Good afternoon, and welcome to The Oncology Institute's First Quarter 2024 Earnings Conference Call. Today's call is being recorded. And we have allocated 1 hour for prepared remarks and Q&A. At this time, I would like to turn the conference over to Mihir Shah, Chief Financial Officer at TOI. Thank you. You may begin.

The press release announcing The Oncology Institute's results for the first quarter of 2024 are available at the Investors section of company's website, theoncologyinstitute.com. A replay of this call will also be available at the company's website after the conclusion of this call. Before we get started, I would like to remind you of the company's safe harbor language included within the company's press release for the first quarter 2024. Management may make forward-looking statements including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. For further discussions of risks related to our business, see our filings with SEC. This call will also discuss non-GAAP financial measures, such as adjusted EBITDA. A reconciliation of this non-GAAP measures to the most comparable GAAP measures are included in the earnings release furnished to the SEC and available on our website. Joining me on the call today is our CEO, Dan Virnich. Following our prepared remarks, we will open the call for your questions. With that, I will turn the call over to Dan.

Thank you, Mihir. Good afternoon, everyone, and thank you for joining our first quarter call. In Q1 2024, our revenue grew 24% compared to Q1 2023 driven by an astounding 64% increase in oral drug revenue in the same period. The first quarter of 2024 saw TOI hit some significant milestones related to growth with 7 new capitation and value-based contracts signed across 3 states, our highest number ever in a quarter. Full year capitation revenue related to our 7 contracts signed in Q1 is estimated to be in the range of $16 million and includes expansion of our risk business in both medical and radiation oncology. We are expecting termination of 1 legacy capitation contract in California in Q3, which we believe will be offset by better-than-expected new capitation contract starts and continued growth in our oral drug business. And as a result, we are not changing full year guidance at this time. As noted, Q1 also saw TOI hitting a record amount of prescription sales and revenue through our medically-integrated dispensaries and pharmacy with over 4,500 fills representing over $39 million in revenue in Q1. Oral drug gross profit in the segment remains on track to expectations at $31 million for the full year due to outperformance of top line. Our newly acquired pharmacy in California continues to exceed expectations, and our latest projection shows incremental growth of over $45 million from this location from full year 2023. Despite top line outperformance, the first quarter came with challenges, particularly related to drug margin compression on both Part B and D drugs with the transition in direct and indirect remuneration or DIR fees to point of sale, an intermittent disruption to collections due to the Change Healthcare cyberattack, which was deemed to be not material. In addition to the…

Thank you, Dan, and good afternoon, everyone. Consolidated revenue for Q1 2024 was $94.7 million, an increase of 24.2% compared to Q1 2023 and a 10.3% increase compared to Q4 2023. Gross profit in Q1 2024 was $11.97 million, a decrease of 16.8% compared to Q4 2023. This decrease is attributed to the lower IV and oral reimbursement Dan previously mentioned. SG&A remains flat despite the strong growth in our top line. SG&A, including depreciation and amortization, was $29.9 million in Q1 2024, a decrease of 50 basis points compared to Q1 2023. As a percentage of revenue, SG&A including depreciation and amortization, was 31.6% in the quarter, down 300 basis points from Q4 2023 and 790 basis points from Q1 2023. Loss from operations for Q1 2024 was $18 million, a decrease of $14.9 million compared to Q1 2023. Net loss for Q1 2024 was $19.9 million, an improvement of $10.1 million compared to Q1 2023, primarily due to goodwill impairment charges of $16.9 million in Q1 2023 that did not occur in Q1 2024. Offset by gains in the fair value of earnout and derivative liabilities of $4.2 million in the prior year quarter that did not occur in the same quarter of the current year. Adjusted EBITDA for Q1 2024 was negative $10.9 million. As of end of Q1 2024, our cash and cash equivalent balance was $36.1 million, and we had $29.7 million in short-term investments for a total of $65.8 million of cash, cash equivalent and short-term investments. The impact of Q1 operating losses, the Change Healthcare impact and AR lag in our new pharmacy resulted in reduction of cash and cash equivalents of $17 million related to Q4 2023. Thanks to our swift response to Change Healthcare situation and work around pharmacy collections, we project the cash flow impact to be simply one-off timing without full year impact on cash flow. I will now turn it back to Dan for closing comments.

Thanks, Mihir. I want to close our call by providing an update on progress towards our 4 key strategic priorities at The Oncology Institute. Priority number one, eliminate cash burn. While we had year-over-year improvement in burn relative to Q1 2023, the drug margin compressions in Q1 did result in higher use of cash than Q4. We are confident that this will improve over the remainder of 2024 as a result of both our already signed and near-term growth in new contracts, procurement improvement efforts and ongoing efforts to ensure we tightly manage SG&A down as a percent of revenue following our restructure last year. Priority number two, grow and drive margin in our legacy markets. Our newly signed medical and radiation oncology contracts in California and Nevada represent important new partnerships, an expansion of our risk across both radiation and medical oncology. These new partnerships, coupled with outperformance on orals through our California pharmacy will continue to help drive profitability in our legacy markets. We will adjust variable staffing related to areas served by our one terminating contract to mitigate margin compression. Priority number three, improving new markets. Our first full quarter of capitation in Florida with Elevance has gone well as we welcomed new patients to our clinics, and we anticipate several other near-term capitation arrangements in this market. As already mentioned, we are also starting services in Oregon in Q4 through another new capitation deal signed this quarter. This new deal represents tremendous opportunity to improve quality and utilization versus the legacy high rate seen in this market. Priority number four, leading the value-based oncology market. Our significant uptick in new capitation contracts signed and continued momentum in our new contract pipeline represents validity of our model with payers as risk-bearing primary care groups and health plans seek partnership with TOI to help manage the unsustainable cost trends in oncology. We strongly believe we can continue to advance this lead for the patients and payers that we serve, and we look forward to updating you on our continued progress toward our key priorities on our next earnings call. With that, we're now ready to take your questions. Operator?

[Operator Instructions] The first question comes from the line of Jack Slevin with Jefferies.

I want to start with the DIR impacts in both IV and on the dispensary side. Just wondering if you can give a little more color in terms of how heavily that was weighted in each of those areas? Did one side see a little bit more than the next? And then maybe sort of using that as a jumping off point for how you're thinking about progression of margins throughout the year. Obviously, patient services margins came down pretty significantly under some of those headwinds. I'm just trying to get a sense for how you're thinking that's going to progress. Is it sort of more gradual? Is there a snap back in Q2? I just want to understand what the way of thinking is.

Jack, thanks for the great question. I think there's a couple of factors that impacted drug margins in Q1 on our fee-for-service business that we expect to see improved throughout the course of the year. The first factor, which we deal with every year is seasonality, as we commented about on our earnings call. So we've already started to see that improve in April and expect that trend to continue to improve over the course of the year, driven by both changes in the level of sophistication we're bringing to procurement and just that seasonality impact. The DIR fee issue, which is the other major factor that we faced in Q1, which compressed margins on our fee-for-service drugs. Again, I think there's industry-wide momentum on driving change in that throughout the rest of the year. But the time course of that is really hard to predict at this point. So again, we're trying to control the factors we can and expect the remaining 3 quarters of the year to drive improvement in those margins, but it's hard to say at what pace that DIR fee issue will resolve itself.

Got it. That's really helpful. And next, Mihir, I want to ask on the Change impact. Is the right way to think about that sort of the just over $16 million of AR drag that you saw in the first quarter. Should we just see a reversal of that? Is that a decent way to size up sort of how to think about the snapback in 2Q now that you've resolved that issue.

Yes. So we -- about $15 million of that, we believe, will be timing. Couple of million will be related to the increased revenue that we have seen. So it's just adding slightly more to the working capital for the pharmacy revenue that we added in Q1.

Okay. Got it. Really helpful. And then next, I appreciate all the commentary on the new cap contracts. And it sounds really good. It sounds like there's 1 incremental one to -- when we last spoke on the 4Q call. Maybe just -- I heard the $16 million of annualized revenue. It sounds like a great number. I just want to make sure I got all the commentary on the pacing of how those should launch those 7 contracts. And then maybe if you could touch a little bit more on how the pipeline is looking? Is it still strong? Should we expect to have sort of a steady flow of announcements? Or was it a little bit front loaded as far as the 1Q deals closing for 2024?

Yes. Another great question, Jack. So the contracts were all signed and executed -- the 7 in Q1. The pacing of start on those contracts, the majority of them are Q3 timing for go live. And that's the way to think about that in terms of impact to revenue this year versus full year. I would say on the pipeline question, our pipeline at this point is, I mean, as robust as we've ever seen it. So we've got a lot of good stuff in the near-term pipeline, which we expect to continue to announce over the rest of the year 2024. And I think there's a lot of different reasons for this. I think, one, is just increasing sophistication of our growth team with sort of implementing our model in new markets, expanding our range of clients that we can work with beyond just delegated medical groups to plans and even now employer groups. And then lastly, I think a lot of the top line pressure related to [ D-28 ] has resulted in groups that are taking risks, finding other ways to try and drag their [ MLR ] through finding better ways to manage their specialty costs. So again, phenomenal Q1 in terms of number of contracts signed. I can't promise the exact number for second quarter, but we are seeing a pretty tremendous pipeline ahead of us.

Okay. That's great color, Dan. And then last one for me here. I think all things considered, the cash burn looks really strong. The performance there, considering Change. Normalizing for Change, does it feel like we're sort of in the right ballpark area on cash burn? Or sort of what's the outlook at this point as we regress to the rest of '24?

Yes. So Q1 had cash burn from the AR growth related to change and increase in our pharmacy revenue and also some compression in margin in Q1 that we saw, right? We will see both of them reverse -- AR reverse much faster in Q2 and continue in Q3 or margin compression should also improve in Q2 and Q3. So I would say this would have -- this Q1 would be -- potentially be the extreme scenario of our cash burn.

Ladies and gentlemen, that concludes our question-and-answer session. I would now like to turn the floor over to Daniel Virnich for closing comments.

Thank you so much, and thanks, everyone, who joined our earnings call today. The management team at TOI is incredibly excited about the number of new partnerships that we were able to effectively start in Q1. And look forward to serving patients associated with those new contracts as they go live throughout remainder of 2024. We're also very excited about the near-term prospects in our pipeline related to growth as well as all the activities that our team is taking to again, combat some of the margin compression on the drug side of the business, which we saw in Q1. I would like to thank everyone for joining our call today and look forward to updating you on continued progress in our business in subsequent quarters. Thank you so much.

Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.